On Tuesday, Idexx Laboratories, Inc (NASDAQ: IDXX) opened higher 3.67% from the last session, before settling in for the closing price of $406.65. Price fluctuations for IDXX have ranged from $356.14 to $548.88 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 10.23% annually for the last half of the decade. Company’s average yearly earnings per share was noted 12.29% at the time writing. With a float of $80.20 million, this company’s outstanding shares have now reached $81.60 million.
In an organization with 11000 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 61.08%, operating margin of 28.99%, and the pretax margin is 28.48%.
Idexx Laboratories, Inc (IDXX) Insider Updates
A key investor’s attitude towards the stock of the Diagnostics & Research industry is another important factor to consider. The insider ownership of Idexx Laboratories, Inc is 1.03%, while institutional ownership is 90.13%. The most recent insider transaction that took place on Feb 10 ’25, was worth 4,618,862. In this transaction Executive Vice President of this company sold 9,986 shares at a rate of $462.53, taking the stock ownership to the 8,176 shares. Before that another transaction happened on Feb 10 ’25, when Company’s Officer proposed sale 9,966 for $463.46, making the entire transaction worth $4,618,863.
Idexx Laboratories, Inc (IDXX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 12.29% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 12.89% during the next five years compared to 16.90% growth over the previous five years of trading.
Idexx Laboratories, Inc (NASDAQ: IDXX) Trading Performance Indicators
Check out the current performance indicators for Idexx Laboratories, Inc (IDXX). In the past quarter, the stock posted a quick ratio of 0.90. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.77. Likewise, its price to free cash flow for the trailing twelve months is 42.28.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 10.67, a number that is poised to hit 2.85 in the next quarter and is forecasted to reach 13.50 in one year’s time.
Technical Analysis of Idexx Laboratories, Inc (IDXX)
Let’s dig in a bit further. During the last 5-days, its volume was 0.93 million. That was better than the volume of 0.81 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 94.89%. Additionally, its Average True Range was 15.15.
During the past 100 days, Idexx Laboratories, Inc’s (IDXX) raw stochastic average was set at 55.22%, which indicates a significant decrease from 92.09% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 62.36% in the past 14 days, which was higher than the 36.42% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $425.21, while its 200-day Moving Average is $448.98. However, in the short run, Idexx Laboratories, Inc’s stock first resistance to watch stands at $426.98. Second resistance stands at $432.38. The third major resistance level sits at $441.31. If the price goes on to break the first support level at $412.65, it is likely to go to the next support level at $403.72. Assuming the price breaks the second support level, the third support level stands at $398.32.
Idexx Laboratories, Inc (NASDAQ: IDXX) Key Stats
There are currently 81,039K shares outstanding in the company with a market cap of 34.17 billion. Presently, the company’s annual sales total 3,898 M according to its annual income of 887,870 K. Last quarter, the company’s sales amounted to 954,290 K and its income totaled 216,150 K.
